Executive Leadership Team
A strong vision for the future built on our history of innovation and success.
A vision requires leadership to become reality. Get to know Zimmer Biomet’s leadership team and what makes them uniquely qualified to drive our business.
Chairman, President and Chief Executive Officer
Bryan C. Hanson was appointed President and Chief Executive Officer and a member of the Board of Directors of Zimmer Biomet in December 2017.
Prior to joining Zimmer Biomet, Mr. Hanson served as a member of Medtronic’s Executive Committee and as Executive Vice President and Group President, Minimally Invasive Therapies Group of Medtronic, where he oversaw and provided strategic direction to that approximately $9 billion business.
Prior to joining Medtronic, Mr. Hanson served as Group President, Covidien, with global responsibility for all Covidien business segments. Prior to being elevated to that newly created position, Mr. Hanson served as Group President, Medical Devices & U.S. of Covidien and prior to that, he served as Group President, Surgical Solutions and President, Energy-based Devices. Mr. Hanson began his career with Covidien in 1992. He holds a Bachelor of Science degree in Finance from Florida State University. He also completed the Kellogg School of Management Finance for Executives program in 2010 and the Harvard Executive Education in Leadership program in 2013. Mr. Hanson serves on the board of the Advanced Medical Technology Association (AdvaMed), the medical device industry’s association and is a member of the International Board Committee. He also serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.
Senior Vice President and Chief Strategy Officer
Rachel Ellingson was appointed Senior Vice President and Chief Strategy Officer in April 2018.
Prior to joining the Company, Ms. Ellingson served as Vice President, Corporate Strategy and as a member of the executive leadership team at St. Jude Medical.
Before joining St. Jude Medical, she served as Vice President, Business Development and Investor Relations at AGA Medical Corporation. Previously, she served in a number of leadership roles in investment banking firms, including Bank of America and Cowen & Company. Ms. Ellingson holds a Bachelor of Arts degree from the University of Rhode Island and an MBA in Finance from the University of Connecticut.
Senior Vice President and Chief Transformation Officer
Ellie Humphrey was appointed Chief Transformation Officer in January 2021. She is responsible for overseeing strategic business growth and transformation initiatives across Zimmer Biomet.
Prior to joining Zimmer Biomet, Ms. Humphrey served as Vice President, Enterprise Excellence and Business Transformation at Medtronic. During her 11-year tenure with the company, she held several leadership roles with a focus on defining the company’s global growth strategy, including portfolio, resource and investment allocation, and performance management. Previously, Ms. Humphrey spent eight years at McKinsey & Company advising corporate clients with a focus on growth, commercial, operational and business development strategies. She holds a JD from the University of Virginia School of Law, MBA from the Darden School of Business, and an AB, cum laude, from Harvard College.
David J. Kunz
Senior Vice President, Global Quality and Regulatory Affairs
David Kunz was appointed Senior Vice President, Global Quality, Clinical and Regulatory Affairs in April 2016. He is responsible for providing strategic and operational direction to achieve Quality and Regulatory Excellence across the organization and he chairs the Company’s Quality Excellence Steering Committee.
Mr. Kunz joined the Company (then Zimmer) in 2011 as Vice President, Regulatory Affairs and Quality Assurance for the Spine division. Prior to joining Zimmer, he served as Vice President, Quality Assurance of Ecolab, where he led a supply chain network including nine chemical plants and two equipment plants.
Previously, he spent 13 years at Guidant/Boston Scientific Corporation in a variety of leadership positions, most recently as the Director of Supplier Quality Assurance for the CRV Division. He began his career at the Naval Nuclear Propulsion Program Headquarters as a mechanical engineer. Mr. Kunz holds a Bachelor of Science and an MBA from the University of Minnesota. He is a certified Nuclear Engineer and previously was a certified Licensed Professional Mechanical Engineer.
Senior Vice President, Global Chief Compliance Officer and Associate General Counsel, Asia Pacific
Angela Main was appointed Senior Vice President, Global Chief Compliance Officer and Associate General Counsel, Asia Pacific in June 2015. She is responsible for the provision of compliance advice and ethical solutions to the Zimmer Biomet organization, including developing, operating and monitoring the Company’s Compliance Program.
Ms. Main served as Vice President, Legal and Compliance, Asia Pacific for Zimmer Biomet from September 2010 to June 2015. Prior to joining the Company in 2010, she worked for Covidien in Singapore, Lloyds TSB Bank plc in London and Texas Instruments in its European and Asia Pacific regional offices.
She has extensive international legal and compliance experience in the healthcare, financial services and technology sectors.
Keri P. Mattox
Senior Vice President, Investor Relations and Chief Communications Officer
Keri P. Mattox was appointed Senior Vice President, Investor Relations and Chief Communications Officer in January 2020. She is responsible for strategically integrating, aligning and driving investor relations, communications and philanthropy functions and activities.
Prior to joining the Company, Ms. Mattox served as Global Lead, Integrated Corporate Communications at W2O Group, an international healthcare-focused marketing and communications firm. There she was responsible for strategically shaping and expanding the firm’s global corporate communications, investor relations, crisis communications, M&A, board engagement and corporate social responsibility/foundation capabilities and offering.
Prior to W2O, Ms. Mattox was Vice President, Corporate & Investor Relations at AmerisourceBergen, a healthcare company ranked #10 on the Fortune 500 in 2019 with nearly than $170 billion in annual revenue. She also held executive leadership team level positions at Endo International and Auxilium Pharmaceuticals and spent more than 10 years at communications agencies in leadership positions. Earlier in her career, Ms. Mattox was a reporter with Hearst Newspapers. She holds a B.A. from Boston University and an M.A. in Journalism from the University of Maryland.
Senior Vice President, General Counsel and Secretary
Chad Phipps was appointed Senior Vice President, General Counsel and Secretary in May 2007. He has global responsibility for the Company’s Legal Affairs and he serves as Secretary to the Board of Directors. Mr. Phipps also oversees the Company’s Government Affairs activities.
Mr. Phipps joined the Company (then Zimmer) in September 2003. Prior to joining Zimmer, he served as Vice President and General Counsel of L&N Sales and Marketing, Inc. in Pennsylvania and he practiced law with the firm of Morgan, Lewis & Bockius in Philadelphia, focusing on corporate and securities law, mergers and acquisitions and financial transactions.
Mr. Phipps holds a Bachelor of Arts, magna cum laude, from Rollins College and a J.D. from Villanova University School of Law.
Vice President, Controller and Chief Accounting Officer
Paul Stellato was appointed Vice President, Controller and Chief Accounting Officer of Zimmer Biomet in May 2022.
Prior to joining Zimmer Biomet, Mr. Stellato was a member of Xylem Inc.’s finance leadership team, where he most recently served as Vice President Finance, Global Business Services. Prior to that, he served as Xylem’s Vice President, Controller and Chief Accounting Officer and as Vice President Finance, Financial Planning and Analysis.
Previously, Mr. Stellato spent eight years at ITT Corporation, where he held various roles of increasing responsibility in the finance organization, including General Auditor and Manager, Investor Relations. Mr. Stellato spent the early part of his career in public accounting with both Andersen and Ernst & Young. He holds a Bachelor of Science in Accountancy from Villanova University and an MBA from the Stern School of Business at New York University. He is also a Certified Public Accountant.
Senior Vice President and Chief Information Officer
Zeeshan Tariq was appointed Chief Information Officer in July 2016.
Prior to joining the Company, Mr. Tariq spent 17 years at Medtronic, where he served in a number of positions of increasing responsibility, most recently as Vice President and Chief Information Officer, Cardiovascular Group.
Prior to joining Medtronic, he worked in the Management Consulting, Systems Consulting and Banking industries. Mr. Tariq holds a Bachelor of Business Administration in Finance, Economics and Management Information Systems from the University of Nebraska; a Master of Science in Software Engineering from the University of Minnesota; and an MBA from the Carlson School of Management.
Chief Operating Officer
Ivan Tornos joined Zimmer Biomet in November 2018 as Group President, Orthopedics, and a year later was named Group President, Global Businesses and the Americas. He was appointed as Chief Operating Officer in March 2021. In addition to his continued leadership of the Americas region, Mr. Tornos also oversees the Europe, Middle East and Africa (EMEA) region. Prior to joining Zimmer Biomet, Mr. Tornos served as Worldwide President of the Global Urology, Medical and Critical Care Division of Becton, Dickinson and Company. Prior to that, he was with C.R. Bard in positions of increasing responsibility, most recently serving as President, Europe, Middle East and Africa Regions. Before joining C.R. Bard, Mr. Tornos served as Vice President and General Manager of the Americas Pharmaceutical and Medical/Imaging segments of Covidien International. Before that, Mr. Tornos served as International Vice President, Business Development and Strategy with Baxter International Inc. and prior to that, he spent over a decade in leadership assignments around the globe with Johnson & Johnson.
Mr. Tornos is an alumnus of the Harvard Business School, having graduated from the Advanced Management Program and also completed leadership and management programs at the Cox School of Business of Southern Methodist University. He finalized post-MBA work at the Wharton School of the University of Pennsylvania (CPD Marketing/Finance), holds an MBA from the University of Miami School of Business and a BBA in Finance and International Marketing and Management from the University of Georgia Terry College of Business.
Kenneth R. Tripp
Senior Vice President, Global Operations and Logistics
Kenneth Tripp was appointed Senior Vice President, Global Operations and Logistics in April 2018.
Prior to joining the Company, Mr. Tripp served as Senior Vice President, Manufacturing at Cardinal Health. Prior to joining Cardinal Health, he served as the Vice President of Operations of the Patient Monitoring and Recovery business at Medtronic.
Mr. Tripp is retired from 25 years of service in the U.S. Navy and U.S. Navy Reserve. Mr. Tripp holds a Bachelor of Arts in History and an MBA in Strategies in Organizational Leadership from Ashford University.
Executive Vice President and Chief Financial Officer
Suketu Upadhyay was appointed Executive Vice President and Chief Financial Officer in July 2019.
Prior to joining Zimmer Biomet, Mr. Upadhyay served as Senior Vice President, Global Financial Operations at Bristol-Myers Squibb from November 2016 until June 2019. Before joining Bristol-Myers Squibb, he served as Executive Vice President and Chief Financial Officer of Endo International from September 2013 to November 2016.
Prior to his tenure at Endo International, Mr. Upadhyay served as Interim Chief Financial Officer as well as Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer of Becton, Dickinson and Company (BD). Prior to his role as BD’s Interim Chief Financial Officer and Corporate Controller, Mr. Upadhyay was the Senior Vice President of Global Financial Planning and Analysis and also held the role of Vice President and Chief Financial Officer of BD’s international business. Before joining BD in 2010, Mr. Upadhyay held a number of leadership roles across AstraZeneca and Johnson & Johnson. These roles included the Global Head of R&D Finance, Head of Commercial Finance, Plant Controller, and Director of Business Development Finance. His experience spans over 20 years in the health care industry in financial roles of increasing responsibility covering all major areas of a fully integrated life sciences business. In addition, his experience covers businesses of varying size and scale and at different points of maturity. Mr. Upadhyay spent the early part of his career in public accounting with KPMG, and earned his CPA designation* in 1996 and his CMA designation* in 2002. He holds a Bachelor of Science in Finance from Albright College and an MBA from The Fuqua School of Business at Duke University. (* Inactive)
Senior Vice President and Chief Human Resources Officer
Ms. Winkler joined Zimmer Biomet in February 2020 as Global Vice President of HR for the Global Business Group and was appointed as Chief Human Resources Officer in March 2021.
Prior to joining Zimmer Biomet, Ms. Winkler served as a Worldwide Vice President of Human Resources in the Cardinal Health Medical Segment where she was responsible for 10,000 employees in over 70 countries. Before that, she served as the Global Head of Human Resources for Finance and Procurement at Johnson & Johnson (J&J). In this role, Ms. Winkler was the HR leader for the Chief Financial Officer of J&J and a member of the CFO’s senior staff, responsible for 6,000 employees worldwide. During her tenure at J&J, she served on a number of Global Management Boards as the HR leader for integrated, commercial businesses as well as large scale global functions including the Corporate Office of Science and Technology, Research & Development and Corporate Affairs.
Ms. Winkler received a Master of Science in Human Resources Development from Barry University, a Bachelor of Arts in Communications from Florida Atlantic University and an Executive Leadership Coaching Certification from Georgetown University.
Group President, Asia Pacific
Sang Yi was appointed President, Asia Pacific effective June 2015. He is responsible for the sales, marketing and distribution of products in the Asia Pacific region.
Mr. Yi joined the Company (then Zimmer) in March 2013 as Senior Vice President, Asia Pacific. Before joining Zimmer, he served as Vice President and General Manager of St. Jude Medical for Asia Pacific and Australia from 2005 to 2013. Prior to that, Mr. Yi held several leadership positions over a ten-year period with Boston Scientific Corporation, ultimately serving as Vice President for North Asia. Mr. Yi holds a Bachelor of Science in Electrical Engineering from the University of South Florida.
Wilfred van Zuilen
President, Europe, Middle East and Africa
Wilfred van Zuilen was appointed President of Europe Middle East and Africa (EMEA) in June 2021. He is responsible for the marketing, sales and distribution of products, services and solutions in the region.
Prior to joining Zimmer Biomet, Mr. van Zuilen served as Regional Vice President, North Western Europe (United Kingdom, Ireland, Nordics and Benelux) at Medtronic. Prior to that, he led Medtronic’s Restorative Therapies Group of businesses for EMEA and has also held regional leadership positions with Covidien, Novartis and Edwards Lifesciences. Mr. van Zuilen holds a bachelor’s degree in Business Economics from Erasmus University in Rotterdam.
All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.